Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ: SAGE )

7.540 +1.990 (+35.86%)
Streaming Delayed Price Updated: 2:41 PM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Where Sage Therapeutics Stands With Analysts
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company... 
Via Benzinga
56 Biggest Movers From Yesterday
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead... 
Via Benzinga
Why A Biogen-Sage Drug Flopped — And Could Still Be Approved
The companies tested a combination of zuranolone and depression drugs. 
Via Investor's Business Daily
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral... 
Via Benzinga
Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
From Sage Therapeutics, Inc.
Via Business Wire
New Psychedelics ETF Launches On NYSE Arca
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)... 
Via Benzinga
Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
From Sage Therapeutics, Inc.
Via Business Wire
Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S.
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
5 Value Stocks In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Sage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises
From Sage Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
From Sage Therapeutics, Inc.
Via Business Wire
5 Value Stocks To Watch In The Healthcare Sector
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples... 
Via Benzinga
Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone... 
Via Benzinga
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Host Sage FutureCast Webcast
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Kiromic BioPharma (NASDAQ:KRBP) ... 
Via Benzinga
What 8 Analyst Ratings Have To Say About Sage Therapeutics
Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings ... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Needham boosted Paycom Software, Inc. (NYSE:PAYC) ... 
Via Benzinga
Sage Therapeutics Inc (SAGE) Q3 2021 Earnings Call Transcript
SAGE earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
How Bad Are Sage Therapeutics's Earnings? | Return On Capital Employed
Sage Therapeutics (NASDAQ:SAGE) brought in sales totaling $1.44 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 21.17%, resulting in a... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.